Skip to contentM
Milestone Pharmaceuticals Inc.
M
MISTMilestone Pharmaceuticals Inc. Q1 2025 · 10-Q
Revenue$0.00$0.00no prior Q1 2024 on file Net Income-$20.76M-$20.76MN/M vs Q1 2024 EPS Diluted-$0.31-$0.31N/M vs Q1 2024 Operating Income-$20,523,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Milestone Pharmaceuticals Inc. · CIK 1408443 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,958,000— ended Mar 31, 2025 · filed May 14, 2025 · 44 d after period end